嵌合抗原受体在对抗多发性骨髓瘤中领先。
CARs in the Lead Against Multiple Myeloma.
作者信息
Ormhøj Maria, Bedoya Felipe, Frigault Matthew J, Maus Marcela V
机构信息
Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, 149 13th Street, Charlestown, MA, 02129, USA.
Harvard Medical School, Boston, MA, USA.
出版信息
Curr Hematol Malig Rep. 2017 Apr;12(2):119-125. doi: 10.1007/s11899-017-0373-2.
Abstract
The recent clinical success of CD19-directed chimeric antigen receptor (CAR) T cell therapy in chronic and acute leukemia has led to increased interest in broadening this technology to other hematological malignancies and solid tumors. Now, advances are being made using CAR T cell technology to target myeloma antigens such as B cell maturation antigen (BCMA), CD138, and kappa-light chain as well as CD19 on putative myeloma stem cells. To date, only a limited number of multiple myeloma patients have received CAR T cell therapy but preliminary results have been encouraging. In this review, we summarize the recently reported results of clinical trials conducted utilizing CAR T cell therapy in multiple myeloma (MM).
摘要
CD19导向的嵌合抗原受体（CAR）T细胞疗法在慢性和急性白血病治疗中取得的近期临床成功，引发了人们对将该技术拓展至其他血液系统恶性肿瘤和实体瘤的更多兴趣。目前，正在利用CAR T细胞技术靶向骨髓瘤抗原，如B细胞成熟抗原（BCMA）、CD138、κ轻链以及假定的骨髓瘤干细胞上的CD19。迄今为止，仅有少数多发性骨髓瘤患者接受了CAR T细胞疗法，但初步结果令人鼓舞。在本综述中，我们总结了近期报道的利用CAR T细胞疗法治疗多发性骨髓瘤（MM）的临床试验结果。
相似文献
1
CARs in the Lead Against Multiple Myeloma.嵌合抗原受体在对抗多发性骨髓瘤中领先。
Curr Hematol Malig Rep. 2017 Apr;12(2):119-125. doi: 10.1007/s11899-017-0373-2.
2
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤和实体瘤：临床数据现状、当前局限性和展望。
Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003.
3
CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.嵌合抗原受体T细胞及其他用于多发性骨髓瘤的细胞疗法：2018年更新
Am Soc Clin Oncol Educ Book. 2018 May 23;38:e6-e15. doi: 10.1200/EDBK_200889.
4
Recent updates on CAR T clinical trials for multiple myeloma.多发性骨髓瘤嵌合抗原受体 T 细胞临床试验的最新进展。
Mol Cancer. 2019 Nov 5;18(1):154. doi: 10.1186/s12943-019-1092-1.
5
Chimeric antigen receptor T-cell therapies for multiple myeloma.用于多发性骨髓瘤的嵌合抗原受体T细胞疗法。
Blood. 2017 Dec 14;130(24):2594-2602. doi: 10.1182/blood-2017-06-793869. Epub 2017 Sep 19.
6
CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.用于治疗多发性骨髓瘤的靶向B细胞成熟抗原的嵌合抗原受体T细胞疗法
Clin Adv Hematol Oncol. 2018 Dec;16(12):804-806.
7
CAR T-cell therapy: is it prime time in myeloma?嵌合抗原受体 T 细胞疗法：在骨髓瘤中是黄金时期吗？
Blood Adv. 2019 Nov 12;3(21):3473-3480. doi: 10.1182/bloodadvances.2019000370.
8
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.B 细胞成熟抗原是多发性骨髓瘤过继性 T 细胞治疗的一个有前途的靶点。
Clin Cancer Res. 2013 Apr 15;19(8):2048-60. doi: 10.1158/1078-0432.CCR-12-2422. Epub 2013 Jan 23.
9
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?嵌合抗原受体T细胞疗法治疗多发性骨髓瘤：我们目前的状况及未来走向？
Leuk Lymphoma. 2018 Sep;59(9):2056-2067. doi: 10.1080/10428194.2017.1393668. Epub 2017 Nov 6.
10
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.嵌合抗原受体修饰 T 细胞治疗实体瘤：现状与展望。
Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11.
引用本文的文献
1
The management of multiple myeloma patients accompanied with disseminated intravascular coagulation before receiving LCAR-B38M therapy.接受LCAR - B38M治疗前伴有弥散性血管内凝血的多发性骨髓瘤患者的管理
Discov Oncol. 2025 Apr 29;16(1):631. doi: 10.1007/s12672-025-02448-9.
2
CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects.基于嵌合抗原受体 T 淋巴细胞的细胞疗法；自杀基因在机制论证、应用和生物安全性增强方面的作用：消除副作用的新机遇。
Front Immunol. 2024 Jul 18;15:1333150. doi: 10.3389/fimmu.2024.1333150. eCollection 2024.
3
From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma.从长矛到三叉戟：升级嵌合抗原受体T细胞疗法在多发性骨髓瘤治疗中的武器库
Heliyon. 2024 Apr 21;10(9):e29997. doi: 10.1016/j.heliyon.2024.e29997. eCollection 2024 May 15.
4
A second-generation CD38-CAR-T cell for the treatment of multiple myeloma.用于治疗多发性骨髓瘤的第二代 CD38-CAR-T 细胞。
Cancer Med. 2023 May;12(9):10804-10815. doi: 10.1002/cam4.5818. Epub 2023 Apr 11.
5
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.针对免疫球蛋白 J 链的广泛适用的 TCR 为基础的多发性骨髓瘤治疗方法。
J Hematol Oncol. 2023 Feb 27;16(1):16. doi: 10.1186/s13045-023-01408-6.
6
Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.嵌合抗原受体 T（CAR-T）细胞：血液系统恶性肿瘤的新型细胞治疗方法。
Cancer Med. 2023 Apr;12(7):7844-7858. doi: 10.1002/cam4.5551. Epub 2022 Dec 30.
7
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.西达基奥仑赛治疗复发/难治性多发性骨髓瘤患者：CARTITUDE-1（2 期）日本队列研究。
Cancer Sci. 2022 Dec;113(12):4267-4276. doi: 10.1111/cas.15556. Epub 2022 Oct 7.
8
Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials.嵌合抗原受体工程 T 细胞治疗血液系统恶性肿瘤：临床试验更新。
Cancer Immunol Immunother. 2022 Oct;71(10):2301-2311. doi: 10.1007/s00262-022-03163-y. Epub 2022 Feb 23.
9
Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma.B 细胞成熟抗原表达与多发性骨髓瘤的分类、分期及预后因素的关系研究。
Front Immunol. 2021 Nov 18;12:724411. doi: 10.3389/fimmu.2021.724411. eCollection 2021.
10
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.基于卡非佐米的治疗方案中硼替佐米和（或）来那度胺耐药对复发/难治性多发性骨髓瘤患者预后的影响：京都临床血液学研究组，亚洲患者的多中心、前瞻性、观察性研究。
Cancer Rep (Hoboken). 2022 Feb;5(2):e1476. doi: 10.1002/cnr2.1476. Epub 2021 Jun 14.
本文引用的文献
1
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.自杀基因修饰的抗CD33重定向嵌合抗原受体T细胞用于急性髓系白血病的体外临床前验证
PLoS One. 2016 Dec 1;11(12):e0166891. doi: 10.1371/journal.pone.0166891. eCollection 2016.
2
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.表达抗B细胞成熟抗原嵌合抗原受体的T细胞可使多发性骨髓瘤缓解。
Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.
3
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.多发性骨髓瘤：2016年诊断、风险分层及管理的最新进展
Am J Hematol. 2016 Jul;91(7):719-34. doi: 10.1002/ajh.24402.
4
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.针对恶性肿瘤相关κ轻链的T淋巴细胞的临床反应。
J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.
5
Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.在新型药物时代，多发性骨髓瘤初始治疗后的早期复发预示着不良预后。
Leukemia. 2016 Nov;30(11):2208-2213. doi: 10.1038/leu.2016.147. Epub 2016 May 23.
6
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.成年B细胞急性淋巴细胞白血病患者中具有特定CD4+:CD8+组成的CD19嵌合抗原受体T细胞。
J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.
7
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.用于治疗多发性骨髓瘤的靶向CD19的嵌合抗原受体T细胞
N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.
8
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.嵌合抗原受体T细胞在复发难治性慢性淋巴细胞白血病中持续存在并诱导持续缓解。
Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
9
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.4-1BB共刺激可改善嵌合抗原受体的持续性信号传导所诱导的T细胞耗竭。
Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.
10
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
Zotero 插件